CHICAGO, March 12 /PRNewswire-FirstCall/ -- The Female Health Company (NYSE Alternext: FHC) - today announced plans to install six more production lines for its FC2 Female Condom(TM), increasing its annualized FC2 production capacity in Malaysia from 30 million units to approximately 75-80 million units.
Currently, The Female Health Company is manufacturing its second-generation product, FC2, on four production lines in Malaysia. The Company, in conjunction with its Indian partner, HLL Lifecare Limited, currently produces FC2 on a fifth production line located in Kochi, India.
Mike Pope, V.P., U.K. and Malaysian operations indicated: "The Malaysian production expansion will bring the total FC2 female condom manufacturing capacity to an annualized rate of approximately 85 million units by early in the fourth quarter of calendar year 2009."
"Based on growing demand for the female condom reported by our major public sector customers that are involved in the global battle against the HIV/AIDS pandemic and the recent approval of FC2 by the U.S. Food and Drug Administration, we have elected to increase FC2 production capacity as noted," stated O.B. Parrish, Chief Executive Officer of The Female Health Company. "The demand for the female condom has been increasing rapidly with unit growth of 34% for FY 2008."
The approval by FDA permits sale of FC2 in the United States and purchases by the United States Agency for International Development for distribution in HIV/AIDS prevention programs throughout the world.
The Company is very pleased that the lower cost FC2 will now increase access by women to the Female Condom on a global basis
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC Female Condom(R) (FC1) and the FC2 Female Condom(T
|SOURCE The Female Health Company|
Copyright©2009 PR Newswire.
All rights reserved